Allergan Downgraded by Buckingham Research to “Neutral” (AGN)
Allergan opened at 111.47 on Thursday. Allergan has a 52-week low of $81.28 and a 52-week high of $111.84. The stock’s 50-day moving average is currently $107.1. The company has a market cap of $33.227 billion and a price-to-earnings ratio of 31.14.
Allergan last released its earnings data on Tuesday, February 5th. The company reported $1.15 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.20 by $0.05. The company had revenue of $1.48 million for the quarter, compared to the consensus estimate of $1.51 million. During the same quarter in the prior year, the company posted $1.00 earnings per share. The company’s quarterly revenue was up 7.6% on a year-over-year basis. Allergan has set its Q1 guidance at $0.94-0.96 EPS and its FY13 guidance at $4.75-4.83 EPS. On average, analysts predict that Allergan will post $4.76 earnings per share for the current fiscal year.
AGN has been the subject of a number of other recent research reports. Analysts at TheStreet reiterated a “buy” rating on shares of Allergan in a research note to investors on Wednesday, February 27th. Separately, analysts at SunTrust reiterated a “buy” rating on shares of Allergan in a research note to investors on Thursday, February 21st. They now have a $121.00 price target on the stock. Finally, analysts at Zacks reiterated a “neutral” rating on shares of Allergan in a research note to investors on Thursday, February 7th. They now have a $114.00 price target on the stock.
Twenty research analysts have rated the stock with a buy rating, two have issued an overweight rating, and seven have issued a hold rating to the company’s stock. The company currently has an average rating of “overweight” and an average target price of $114.77.
The company also recently declared a quarterly dividend, which is scheduled for Thursday, March 21st. Stockholders of record on Thursday, February 28th will be given a dividend of $0.05 per share. This represents a $0.20 dividend on an annualized basis and a yield of 0.18%. The ex-dividend date of this dividend is Tuesday, February 26th.
Allergan, Inc. is a multi-specialty health care company focused on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter products.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.